Teva and mAbxience partner to develop biosimilar candidate for oncology [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate. It is the second collaboration between the two entities, building on the partnership that began in April 2024. The new global licencing agreement aims to develop an additional oncology biosimilar, reinforcing the alliance between Teva and mAbxience. By combining their expertise and resources, the companies are committed to fostering innovation and improving healthcare accessibility for patients globally. The agreement grants Teva exclusive rights for several markets, including Europe and the US. It is in line with mAbxience's strategy for expansion across the globe and reflects Teva's efforts to grow its portfolio of biosimilars through strategic partnerships. Teva business development executive vice-president Angus Grant said: “This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments. “This coll
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateGlobeNewswire
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 7/31/24 - Beat
TEVA
Sec Filings
- 9/4/24 - Form 4
- 8/14/24 - Form 144/A
- 8/14/24 - Form 144/A
- TEVA's page on the SEC website